Literature DB >> 7537346

"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention.

D R Farley1, A L Weaver, D M Nagorney.   

Abstract

OBJECTIVE: To clarify the "natural history" of unresected cholangiocarcinoma.
DESIGN: We reviewed the outcome in 103 patients with biopsy-proven cholangiocarcinoma managed at our institution during a 5-year period (1980 through 1984) who did not undergo curative resection.
MATERIAL AND METHODS: The study group of 56 men and 47 women had initial manifestations of jaundice (71%), abdominal pain (49%), and weight loss (44%). The histopathologic features were confirmed by operation in 73 patients, percutaneous biopsy in 16, endoscopy in 3, or autopsy in 11. The primary tumor site was the common hepatic duct in 27%, the hepatic bifurcation in 27%, the common bile duct in 26%, the liver in 13%, and the right or left hepatic duct in 6%. Biopsy-proven metastatic lesions were identified in 70 patients, including 18 with proven nodal involvement. Surgical intervention (N = 57) most commonly consisted of biliary decompression (26%), biliary bypass (16%), or cholecystectomy (11%).
RESULTS: The operative mortality was 4% (N = 2). The hospital mortality of medically managed patients was 12%. The survival after the onset of symptoms was 53% at 1 year, 19% at 2 years, and 9% at 3 years. Only four patients (4%) lived more than 5 years. Univariate analysis of all hospitalized patients (N = 90) revealed a survival advantage for women, patients 62 years of age or younger, those with blood group A or O, surgical patients, patients who did not require biliary decompression, and those who received further palliative treatment after any type of biliary decompression. Multivariate analysis showed a survival advantage for patients who underwent surgical exploration and those who had further palliative treatment after either operative or percutaneous biliary decompression.
CONCLUSION: Unresected cholangiocarcinoma is a rapidly fatal process, but early intervention affects the course of the disease and likely prolongs patient survival.

Entities:  

Mesh:

Year:  1995        PMID: 7537346     DOI: 10.4065/70.5.425

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  74 in total

Review 1.  Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

Authors:  Sumera Rizvi; Mitesh J Borad; Tushar Patel; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

2.  Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma.

Authors:  Young Koog Cheon; Tae Yoon Lee; Seung Min Lee; Jung Yoon Yoon; Chan Sup Shim
Journal:  HPB (Oxford)       Date:  2012-01-06       Impact factor: 3.647

3.  Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection.

Authors:  Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

Review 4.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

5.  A rare cause of dilated bile duct incidentally detected on imaging.

Authors:  Kah Poh Loh; Deborah Nautsch; David Desilets; Vaibhav Mehendiratta
Journal:  BMJ Case Rep       Date:  2014-05-23

Review 6.  Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Joseph J Zechlinski; William S Rilling
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

7.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

8.  MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.

Authors:  Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  Cholangiocarcinoma: a 7-year experience at a single center in Greece.

Authors:  Alexandra Alexopoulou; Aspasia Soultati; Spyros-P Dourakis; Larissa Vasilieva; Athanasios-J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

10.  Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Claus von Weyhern; Falko Fend; Jochen Schneider; Bruno Neu; Alexander Meining; Hans Weidenbach; Roland M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.